This announcement just proves the superiority of design and tissue, other companies had to do animal trials for 2 years+ on pigs, sheep and cows before proceeding ahead with human trials.
For Admedus, to have a leading specialist recommend human trials after only having the SAVR implanted in sheep shows beyond doubt that the company has come up with a great revolutionary product that will benefit many heart patients and grow the company.
This announcement just proves the superiority of design and...
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.86 |
Change
-1.040(9.54%) |
Mkt cap ! $203.1M | |||
| Open | High | Low | Value | Volume |
| $10.50 | $10.79 | $9.30 | $1.056M | 106.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 78 | $9.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.00 | 500 | 1 |
View Market Depth
| Last trade - 13.16pm 06/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |